Skip to content
Bored Studies
RecruitingPhase 1/Phase 2

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Aurinia Pharmaceuticals Inc. · NCT07596901

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1, Phase 2
Target enrollment
81
US sites recruiting
11
Study start
April 22, 2026
Record last updated
August 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Being studied: Aritinercept; Placebo

Conditions: Myasthenia Gravis, Generalized

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Adult patients (18-85 years old)
  • Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG
  • Additional inclusion criteria are defined in the protocol

Key Exclusion Criteria

  • Current or medical history of malignancy within the last 5 years
  • Pregnant, breastfeeding or intending to become pregnant during the Study
  • Additional exclusion criteria are defined in the protocol

Recruiting US locations

  • Aurinia Investigational Site

    Pasadena, CA 91106

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Altamonte Springs, FL 32714

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Boca Raton, FL 33487

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Homestead, FL 33033

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Miami, FL 33155

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Miami, FL 33173

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Chicago, IL 60616

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    O'Fallon, IL 62269

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Dearborn, MI 48126

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Flint, MI 48507

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

  • Aurinia Investigational Site

    Houston, TX 77027

    Site contact: Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com

Study contacts (from the official record)

  • Aurinia Clinical Trials Information · 833-606-5975 · clinicaltrials@auriniapharma.com
All phase 1 studies in California →
Study of Aritinercept in Patients With Generalized Myasthenia Gravis (NCT07596901) | Bored Studies